A 15 Week, Phase 2, Double Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Efficacy, Safety and Tolerability of PF 06649751 in Subjects with Motor Fluctuations due to PD

Administered By

Awarded By

Contributors

Start/End

  • July 1, 2016 - December 31, 2018